Affimed Reports Efficacy, Safety Data From Leukemia Treatment Study

MT Newswires Live2024-12-10

Affimed (AFMD) said Monday that AFM28 showed "promising" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study.

The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients, the company said.

The company said AFM28 showed a "favorable" safety profile, with no signs of neurotoxicity or immune-related side effects seen.

Affimed said the assessment of higher dose levels is being planned, based on the safety profile and the likely dose-effect relationship.

Price: 2.27, Change: -0.06, Percent Change: -2.58

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490701191?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490701191","market":"sh","top_or_hot":-1,"title":"Affimed Reports Efficacy, Safety Data From Leukemia Treatment Study","media":"MT Newswires Live","content":"<html><body><p> Affimed (AFMD) said Monday that AFM28 showed \"promising\" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study.</p><p>The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients, the company said.</p><p>The company said AFM28 showed a \"favorable\" safety profile, with no signs of neurotoxicity or immune-related side effects seen.</p><p>Affimed said the assessment of higher dose levels is being planned, based on the safety profile and the likely dose-effect relationship.</p><p>Price: 2.27, Change: -0.06, Percent Change: -2.58</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Affimed Reports Efficacy, Safety Data From Leukemia Treatment Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAffimed Reports Efficacy, Safety Data From Leukemia Treatment Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-10 03:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Affimed (AFMD) said Monday that AFM28 showed \"promising\" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study.</p><p>The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients, the company said.</p><p>The company said AFM28 showed a \"favorable\" safety profile, with no signs of neurotoxicity or immune-related side effects seen.</p><p>Affimed said the assessment of higher dose levels is being planned, based on the safety profile and the likely dose-effect relationship.</p><p>Price: 2.27, Change: -0.06, Percent Change: -2.58</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490701191","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490701191","pubTimestamp":1733770962,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Affimed (AFMD) said Monday that AFM28 showed \"promising\" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 stu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AFMD":"Affimed NV"},"translate_title":"Affimed报告白血病治疗研究的疗效和安全性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFMD":0.9},"content_text":"Affimed (AFMD) said Monday that AFM28 showed \"promising\" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study.The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients, the company said.The company said AFM28 showed a \"favorable\" safety profile, with no signs of neurotoxicity or immune-related side effects seen.Affimed said the assessment of higher dose levels is being planned, based on the safety profile and the likely dose-effect relationship.Price: 2.27, Change: -0.06, Percent Change: -2.58","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490701191","isCrawlerRequest":true}